Arthur L. Rosenthal, Chair
Arthur L. Rosenthal, PhD, joined IBI’s Board of Directors in July 2009 and has been Chairman since 2011. He is also Non-Executive Director and Chair of Compensation Committee for LivaNova, plc, a UK global medical technology company. Prior, Dr. Rosenthal served on the Cyberonics board of directors as a Non-Executive Director and Chair of the Compensation Committee from January 2007 to October, 2015. Since June 2010, he has served as Professor of Practice in the Biomedical Engineering Department at Boston University. Since December 2011, he has also served as CEO of gEyeCue, Ltd., which he co-founded, a development stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. From 2009 to 2012, Arthur was President and CEO and then executive vice chairman of Cappella Medical Devices Ltd. (now ArraVasc Ltd.), a development-stage company focused on novel device solutions for coronary artery disease. From 2002-2008, Arthur was CEO of Labcoat, Ltd. until its acquisition by Boston Scientific Corporation in December 2008. From 1994-2005, Arthur was with Boston Scientific, retiring Senior Vice President, Chief Scientific Officer, and Executive Committee Member.
Sandra Beach Lin, Retired President & CEO, Calisolar Inc.
Ms. Beach Lin brings 30+ years of polymer, technology and innovation experience to the IBI Board, having served in C-suite positions at Celanese Corporation and AveryDennison, and in senior executive roles at Honeywell International and Alcoa. She also brings private company experience to IBI as the retired President & CEO of Calisolar Inc. (now Silicor Materials), a privately-held provider of solar silicon. Ms. Beach Lin is a member of the Board of Directors of WESCO International (NYSE: WCC), American Electric Power (NYSE: AEP) and PolyOne Corporation (NYSE:POL).
Dion Madsen, Senior Managing Partner, Healthcare Fund, BDC Capital
Dion Madsen is Senior Managing Partner of the Healthcare Fund at BDC Capital. Dion brings over 25 years of senior management experience as a financial executive and venture investor, formerly as Founder and Managing Director of Physic Ventures, and as Managing Director of Unilever Technology Ventures, Unilever’s North American corporate venture fund. Prior to Unilever, Dion was Director of Investor Relations at Chiron Corporation where he also worked in Corporate Development, building a new strategy for the company’s $500M BioPharma business. Before moving to San Francisco, Dion spent five years as Partner of RBC Capital Partners’ Life Sciences Venture Fund, the first third-party capital fund in RBC Capital Partners’ history.
Dion is a founding member of C100, a select group of the top 100 Canadians in the San Francisco Bay area, and has sat on the boards of directors of many venture capital funds and companies in the pharmaceutical and health care industries. He has also held the roles of M&A Advisor, Strategic Consultant and CFO for a biotechnology company. He currently sits on the Board of Directors of Interface Biologics, Agrisoma Biosciences, Phemi Health Systems, Xagenic Inc., Zymeworks and Chromatin. He is also a selection committee member of the San Francisco Canadian Technology Accelerator.
Dion is a CFA® charterholder and has a Bachelor of Commerce in Finance and Marketing from the University of Saskatchewan.
Thomas P. Reeves, President & CEO
Mr. Reeves is President and CEO of Interface Biologics. A more detailed description of his credentials is included in the "Our Management" section of this website.
Paul Santerre, Ph.D., Chief Scientific Officer, Interface Biologics Inc.
Dr. Santerre is the founder and Chief Scientific Officer of Interface Biologics and a full professor of biomaterials at the University of Toronto. A more detailed biography is included in the “Our Management” section of this website.
Phil Reddon, Managing Partner, Covington Capital Corporation
Phil joined Covington in 2002 as Vice President, Investments. Before joining Covington, Phil was Managing Director at Bank of Montreal Capital Corporation for six years leading the firm’s technology investment team. Prior to that, Phil was with a Canadian crown corporation where he was involved in lending and investing in technology companies for 6 years. Phil has over 20 years of direct investment experience in early stage technology companies and has sat on the board and driven numerous investments from initial funding, through follow on rounds of financing and exits. Phil has an B.A. from the University of Western Ontario and an H.B.A. from the University of Windsor.
Pieter Wolters, Managing Director, DSM Venturing, VP DSM Innovation Center
Pieter joined DSM in 2012 as Managing Director DSM Venturing and VP at the DSM Innovation Center. Before DSM he gained fifteen years of “startup through commercialization” experience as CEO at OrthAlign, Inc., Aliso Viejo, CA, a pioneer in orthopedic surgical navigation and at IsoTis, Inc., Irvine, CA, a leading regenerative medicine company. Pieter worked the first ten years of his career in international M&A and investment management and holds a law degree from Leiden University, NL. He works and lives in (greater) Boston, MA, USA.